Onal, UgurAkyol, DenizKaya, ArdaBaskol, DilsahKenanoglu, BuseSanlidag, GamzeOnal, Ayse UyanAvsar, Cansu BulutMert, MerveMemetali, SeichanErdem, Hueseyin AytacBozkurt, DevrimSimsir, AdnanBozbiyik, OsmanKahraman, UmitOzgiray, ErkinKorkmaz, PervinCilli, FerihaPullukcu, HusnuYamazhan, TansuTasbakan, Meltem IsikgozArda, BilginUlusoy, SercanSipahi, Oguz Resat2024-11-072024-11-072023-10-010934-9723https://doi.org/10.1007/s10096-023-04660-3https://hdl.handle.net/11452/47542Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.eninfo:eu-repo/semantics/closedAccessTherapyInfectionsDouble carbapenem therapyCarbapenem-resistant klebsiella pneumoniaBacteremiaScience & technologyLife sciences & biomedicineInfectious diseasesMicrobiologyInfectious diseasesMicrobiologyArticle00106395510000112691273421010.1007/s10096-023-04660-3